Upcoming Events

Laurence Crowley Lecture Series with Paul Stoffels

  • Date: Monday, January 23, 2023
  • Time: 6:30 PM - 7:30 PM
  • Venue: UCD Smurfit School
  • Location: UCD Smurfit School

Share this event

Lecture Title:  The Role of the Pharmaceutical Industry in Prolonging Life and Enhancing Quality of Life for Patients Worldwide

Register Here

Each year UCD Smurfit School hosts the annual Laurence Crowley Lecture Series. Running since 2014, this year's lecture  features Paul Stoffels, Chief Executive Officer, Galapagos.

Paul Stoffels Galapagos

Abstract:
How can the pharmaceutical industry better address major global health challenges? How can it provide faster help in regions where expensive and complex innovations are less accessible? And what have we learned from the COVID-19 pandemic and other crises? Pharmaceutical firms that rely on intensive R&D, using complex knowledge for their strategic direction, can contribute to the overall welfare of society by bringing novel and breakthrough drugs to the market by letting the scientists drive what needs to be done. The world is moving towards a massive health crisis: multi-resistant bacteria, pandemic viruses, dementia, heart failure, mental health are all huge problems. Add to that urbanization, refugees, and the economic crisis. It’s essential to prepare for these challenges and the pharmaceutical industry will play a substantial role in achieving these goals.

Paul Stoffels - Chief Executive Officer

Dr Paul Stoffels joined Galapagos as CEO* in April 2022. Prior to that, he was Vice Chairman of the Executive Committee and CSO of Johnson & Johnson, where he set the company wide innovation agenda and led the pharmaceutical R&D pipeline as well as the external initiatives. Before that, he was worldwide Chairman Pharmaceuticals of Johnson & Johnson, which, under his leadership, significantly rejuvenated its product pipeline and adopted a transformational R&D operating model, resulting in the launch of 25 innovative medicines across the globe. Dr Stoffels joined Johnson & Johnson in 2002, with the acquisition of Virco and Tibotec, where he was CEO and Chairman respectively, and where he led the development of several breakthrough products for the treatment of HIV. Dr Stoffels is currently a member of the Supervisory Board of Philips Healthcare in the Netherlands.
* Acting via Stoffels IMC BV

Register Here

Discover our Rankings and Accreditations